Zeke Capital Advisors’s Antares Pharma, Inc. ATRS Stock Holding History

Zeke Capital Advisors’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-10,811	Closed	-$28K	–	766
2018 Q2	$28K	Hold	10,811	–	–	﹤0.01%	632
2018 Q1	$24K	Hold	10,811	–	–	﹤0.01%	649
2017 Q4	$22K	Buy	+10,811	New	+$23.5K	﹤0.01%	569

Other funds holding ATRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MWP

MYCIO Wealth Partners Philadelphia, Pennsylvania $502M AUM 11.65% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Zeke Capital Advisors's ATRS Position: Q3 2018 in Review

Zeke Capital Advisors sold out of Antares Pharma, Inc. (ATRS) in Q3 2018, closing a stake of 10,811 shares — an estimated $28K sold.

Zeke Capital Advisors first reported a position in ATRS in Q4 2017 and held it in 3 quarters. The position peaked at $28K in Q2 2018. 105 funds tracked by Wall St. Rank hold ATRS as of Q3 2018.

Zeke Capital Advisors reported no remaining Antares Pharma, Inc. position as of Q3 2018 after selling out during the quarter.
Zeke Capital Advisors sold 10,811 Antares Pharma, Inc. shares in Q3 2018, an estimated $28K.
Zeke Capital Advisors first reported a position in Antares Pharma, Inc. in Q4 2017 and held it in 3 quarters.
Zeke Capital Advisors's Antares Pharma, Inc. position peaked at $28K in Q2 2018.
105 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q3 2018.

Based on Zeke Capital Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.